Vertex drops one Alios nuc, advances another in all-oral HCV strategy
This article was originally published in Scrip
Executive Summary
A Vertex Pharmaceuticals spokeswoman said the company is "encouraged so far" by positive data for ALS-2200 (VLX-135) for the treatment of hepatitis C virus (HCV), but it will end development for ALS-2158, the other nucleotide analogue it licensed last year from Alios BioPharma in San Francisco.